Original Research ARTICLE
Gray and White Matter Demyelination and Remyelination Detected with Multimodal Quantitative MRI Analysis at 11.7T in a Chronic Mouse Model of Multiple Sclerosis
- 1Center for Neuroimaging Research, Brain and Spine Institute, Paris, France
- 2Pierre and Marie Curie University/INSERM UMR975, Brain and Spine Institute, Paris, France
- 3Department of Neurology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Myelin is a component of the nervous system that is disrupted in multiple sclerosis, resulting in neuro-axonal degeneration. The longitudinal effect of chronic cuprizone-induced demyelination was investigated in the cerebral gray and white matter of treated mice and the spontaneous remyelination upon treatment interruption. Multimodal Magnetic Resonance Imaging and a Cryoprobe were used at 11.7T to measure signal intensity ratios, T2 values and diffusion metrics. The results showed significant and reversible modifications in white matter and gray matter regions such as in the rostral and caudal corpus callosum, the external capsule, the cerebellar peduncles, the caudate putamen, the thalamus, and the somatosensory cortex of treated mice. T2 and radial diffusivity metrics appeared to be more sensitive than fractional anisotropy, axial diffusivity or mean diffusivity to detect those cuprizone-induced changes. In the gray matter, only signal and T2 metrics and not diffusion metrics were sensitive to detect any changes. Immunohistochemical qualitative assessments in the same regions confirmed demyelination and remyelination processes. These multimodal data will provide better understanding of the dynamics of cuprizone-induced de- and remyelination in white and gray matter structures, and will be the basis to test therapies in experimental models.
The myelin sheath is an essential component of the vertebrate nervous system enabling an accelerated conduction of nerve impulses together with reduced energy consumption. In the human central nervous system, several debilitating diseases are secondary to myelin damage, the most frequent being multiple sclerosis (MS), where recurrent episodes of demyelination result in neuro-axonal degeneration. Promoting myelin repair, an endogenous process that was shown to fail as disease progresses, is a crucial therapeutic challenge in MS. Not only should it allow restoration of normal conduction and functional recovery, but it may also prevent axonal and neuronal degeneration. Such a neuroprotective role of myelin could be particularly important in the cortical gray matter (GM) where myelin sheaths, despite being less abundant, could play a crucial role in neuronal survival (Kang et al., 2013). Interestingly the existence of GM demyelinating cortical lesions in the brains of MS subjects, which are now known to be an important hallmark of MS (Kidd et al., 1999; Kutzelnigg et al., 2005; Nelson et al., 2008; Geurts et al., 2011; Mike et al., 2011; Staugaitis et al., 2012), has recently been demonstrated. Such cortical demyelination is thought to appear during the first stages of the disease, but subsequently becomes increasingly pronounced during the later phases. This process could be a contributing factor in disability among MS patients. In addition, efficient remyelinating abilities have been observed in such lesions, with an even higher efficiency than in white matter (WM) lesions (Chang et al., 2012).
The cuprizone (CPZ) mouse model is frequently used to recapitulate demyelination that occurs in MS. Cuprizone is a copper chelator (biscyclohexanone oxaldihydrazone) that causes cell death of the oligodendrocytes, leading to demyelination (see review by Torkildsen et al., 2008). This neurotoxin has been used in mice since 1966 and is administered in food (Carlton, 1966). Mice fed with CPZ were initially described as presenting WM demyelination mainly in the corpus callosum (CC) and in the cerebellar peduncles (CP) (Suzuki and Kikkawa, 1969; Matsushima and Morell, 2001). Recent investigations have pointed that CPZ treated mice were also characterized by an extended GM demyelination occurring in the cerebellar cortex (Skripuletz et al., 2010), in the deep GM, and in the cerebral cortex (Skripuletz et al., 2008, 2011; Xiao et al., 2008). A key feature of the CPZ model is that following withdrawal of the toxin, remyelination takes place spontaneously with a high level of efficacy both in WM and GM areas, especially when a short-duration CPZ exposure paradigm is applied, i.e., 5–6-week treatment (TX) (Skripuletz et al., 2011). When the TX is prolonged for 12 weeks, the remyelination process is delayed and only partly efficient (Armstrong et al., 2006; Skripuletz et al., 2008; Lindner et al., 2009). Overall the CPZ model enables the investigation of the mechanisms of remyelination both in the WM and in the GM, either in optimal or deficient conditions. The development of repair therapies requires methods to monitor myelin dynamics in living individuals. Magnetic Resonance Imaging (MRI) is widely used to study brain disorders. Conventional structural imaging using T2 contrast easily enables the detection of macroscopic WM lesions, however it is not specific of a particular biological abnormality, and generally fails to identify cortical demyelination due to weak spatial resolution and sparse cortical network of fibers in the cortex resulting in poor contrast for myelin. Diffusion-weighted MRI is based on the diffusion of water molecules, which can be restricted by membranes, and can thereby provide differential measurements of myelin and axonal integrity (Song et al., 2002; Bodini et al., 2015). Several MRI studies attempted to visualize demyelination and remyelination in the WM of mice treated with CPZ using different MRI techniques such as T2-weighted imaging, which showed enhanced signal in demyelinated regions (Yu et al., 2004; Merkler et al., 2005; Thiessen et al., 2013), diffusion-weighted imaging (Song et al., 2005; Sun et al., 2006; Wu et al., 2008; Boretius et al., 2012; Zhang et al., 2012) showing increased radial diffusivity (RD) and decreased fractional anisotropy (FA) in demyelinated regions, or magnetization transfer imaging (Zaaraoui et al., 2008; Turati et al., 2015) showing decreased magnetization transfer ratios after demyelination and recovery after remyelination. More recently, WM tract integrity metrics derived from diffusion kurtosis imaging have been shown to be more specific to assess the WM microstructural changes in the CPZ model (Jelescu et al., 2016).
However, most of these studies have focused on the CC, and none has explored the dynamics of GM pathology. We used ultra-high-field MRI and a CryoProbe™ in order to provide increased signal-to-noise ratio (SNR) and resolution to investigate both GM and WM alterations over 7 brain regions during TX and recovery in the chronic CPZ mouse model.
Materials and Methods
All animal experiments were performed in accordance with the European Council Directive (88/609/EEC).
We used C57Bl/6J PLP-GFP L42 transgenic mice, where the fluorescent GFP was spontaneously expressed in myelin. Six 8-week old female mice were fed with 0.2% CPZ and imaged before TX and 12 weeks after TX. The animals were then fed normal chow during 12 additional weeks and weighed on a daily basis. They were imaged at 6 weeks (n = 5) and 12 weeks (n = 4) without TX to monitor recovery. One mouse was sacrificed at 12 weeks of TX and one mouse at 12 weeks of recovery for immunohistochemical assessment.
Throughout all imaging sessions, the animals were anesthetized with 1–1.5% isoflurane (Abbott Animal Health) mixed with oxygen (1:5 O2:air) delivered through a nose cone at a flow rate of 1 L/min. Physiological parameters were recorded via a monitoring system (S.A. Instruments Inc.). The temperature of the animals was maintained at 37°C through a circulating heated water system, and measured with a rectal probe. The respiration of the animals was monitored using a pressure pad positioned under their abdomen.
All images were acquired with an 11.7-T system (Bruker Biospec 117/16 USR horizontal bore, 750 mT/m gradients, Paravision 5.1, Ettlingen, Germany) and a helium-cooled 1H quadrature transmit-receive surface CryoProbe™ for mouse head (Bruker, Ettlingen, Germany). The receiver gain was manually adjusted to optimize the gain over the upper 3/4 of the brain. High-resolution anatomical T2-weighted (T2w) images were acquired with a 2D rapid acquisition with relaxation enhanced sequence; repetition time (TR) = 6000 ms; echo time (TE) = 40 ms; Matrix = 256 × 256; field-of-view (FOV) = 15.36 × 15.36 mm2; resolution = 60 × 60 μm2; slice thickness = 220 μm; number of excitations = 1; acquisition time = 17 min. Parametric T2 maps were obtained from a multi-slice multi-echo sequence with TR = 5500 ms; TE = 15–120 ms/5-ms increments; Matrix = 128 × 128; FOV = 12.8 × 12.8 mm2 (resolution = 100 × 100 μm2); slice thickness = 200 μm; number of excitations = 2; acquisition time = 15 min. Three-dimensional diffusion echo-planar images were acquired with TR = 500 ms; TE = 20 ms; Matrix = 160 × 96 × 32; FOV = 24 × 14.4 × 9.6 mm3 (resolution = 150 × 150 × 300 μm3); 46 directions; b = 1000 s/mm2; δ = 4 ms; Δ = 10 ms; acquisition time = 41 min.
The T2w images were coregistered using the Linear Image Registration Tool from the Oxford Center for Functional MRI of the Brain (Jenkinson and Smith, 2001; Jenkinson et al., 2002). Signal ratios (Sr) were calculated from the coregistered images between the signal in manually-drawn regions of interest (ROIs) in the GM or WM and the signal from the cerebrospinal fluid as done by Yu et al. (2004) and Chandran et al. (2012), using the Image Processing and Analysis in Java software (http://imagej.nih.gov). T2 values were calculated from a pixel-wise regression fit function from the multi-echo sequence using the PV5.1 image sequence analysis tool package. Diffusion parametric maps were also generated from the Paravision 5.1 package. Diffusion metrics such as FA, AD (as a marker of axonal damage), RD (as a marker of myelin damage) and mean diffusivity (MD) were measured.
Anatomical landmarks were used to position the ROIs at the same place in all mice (Figure 1). The ROIs included the rostral and caudal CC (rCC and cCC), the external capsule (EC), the primary somatosensory cortex (S1), the cerebellar peduncles (CP), the dorsal caudate putamen (CPu) and the ventral posteromedial and posterolateral thalamic nuclei (TH). Measurements for a given ROI were averaged from the left and the right hemispheres over 3 adjacent slices.
Figure 1. T2-weighted coronal images of the dynamics of demyelination/remyelination over the course of the pre-TX (A,D,G,J), 12w TX (B,E,H,K) and 12w no TX phases (C,F,I,L). Hyperintensities were detected after 12 weeks (12w) of TX in CPu, EC, and rCC (B); in CP (E); in TH and cCC (H); and in S1 (K). After 12 weeks without TX (C,F,I,L), the signal intensities decreased back. Manually-drawn regions of interest are shown in the middle panel in white.
To compare the experimental groups at different time points, the statistical analysis was performed using the Matlab mutlcompare function for pairwise multiple comparison (Matlab 7.11.0 R2010b, Statistics Toolbox). The results were considered statistically significant when the comparison intervals were disjoint. The p values were corrected for multiple comparisons and considered significant for p < 0.05. Either the comparison intervals or the p-values are provided. Each timepoint for each ROI was compared to the other 3 timepoints. All error bars correspond to the standard error of the mean.
Full recovery was established when the two following conditions were fulfilled: (i) a significant difference was detected between the 12-week TX timepoint and either the 6-week or 12-week recovery timepoints and (ii) no significant difference was found between the pre-TX and the 6-week or 12-week recovery timepoints. Partial recovery was established when either or both of the following conditions were fulfilled: (i) a significantly low difference was detected between the 12-week TX timepoint and either the 6-week or 12-week recovery timepoint and (ii) no significant difference was found between the pre-TX and the 6-week or 12-week recovery timepoints; or when a significant difference was detected between both (i) the 12-week TX timepoint and the 6-week or 12-week recovery timepoints and (ii) between the pre-TX and the 6-week or 12-week recovery timepoints.
Two mice were sacrificed (one at 12 weeks of TX and one at 12 weeks with no TX), and perfused intracardially with 4% paraformaldehyde in phosphate buffer saline. The extracted brains were then post-fixed overnight at 4°C in the same fixative, cryoprotected for several hours at 4°C in phosphate buffer saline containing 30% sucrose, and frozen in melting isopentane. The brains were then sliced in 20 μm thick sections with a Microm cryostat for myelin assessment with PLP/GFP (proteolipid protein/green fluorescent protein). Microscopic scans of whole sections (pixel size 0.25 μm2) were acquired with a Nanozoomer 2.0-RSslide scanner (Hamamatsu Photonics, Hamamatsu Japan). Co-localization of brain regions with MR images was performed using anatomical landmarks from similar slices.
Signal enhancement was clearly visible from the T2w images at 12 weeks of TX in rCC, CPu, EC, CP, cCC, TH, and S1 (Figure 1, middle column) and some recovery was also visible at 12 weeks with no TX (Figure 1, right column) compared to the pre-TX baseline signal (Figure 1, left column).
Measurements of Sr after 12 weeks of TX showed significant enhancement in the superior CP (p < 0.006), TH (p < 0.005), S1 (interval [−15.6; −3.1]), rCC (p < 0.03), cCC (p < 0.004) and EC (p < 0.04) (Figure 2). After recovery (no TX) Sr fully came back to their initial values in TH (p < 0.005 at 12 weeks) and rCC (p < 0.03 at 6 weeks), only partially in S1 (interval [−0.6;13.8]; p < 0.2 at 12 weeks). No significant recovery of Sr was found in CP, CPu, cCC, or EC. However, no significant difference was found between pre-TX and no TX at 6 weeks in EC, which indicated partial recovery in this structure.
Figure 2. Significant increase of Sr after 12 weeks (12 w) of TX in most structures. Sr values came back to initial values after 6 weeks (6 w) or 12 weeks without TX in TH and rCC, partially in S1 and not in CP, Cpu, cCC, or EC. *p < 0.05; **p < 0.01.
T2 values (Figure 3) significantly increased in all GM and WM structures after 12 weeks of TX compared to pre-TX (CPu: p < 0.002; TH: p < 0.02; S1: p < 0.03; rCC: p < 0.01; cCC: p < 0.004; EC: p < 0.004). They then fully returned to initial values without TX in CPu (p < 0.04 at 12 weeks), in TH (p < 0.03 at 6 weeks), in rCC (p < 0.02 at 6 weeks) and in EC (p < 0.002 at 12 weeks). Only partial recovery was found in cCC as a significant difference was found both between the 12-week TX timepoint and the 12-week recovery timepoint, and between the 12-week TX timepoint and the pre-TX timepoint (p < 0.004). The T2 values measurements did not detect any recovery in S1 unlike Sr measurements.
Figure 3. T2 values. Significant increase of T2 in all structures after 12 weeks (12w) of TX. Full or partial recovery after 6 weeks (6w) or 12 weeks without TX in all structures, except in S1. *p < 0.05; **p < 0.01.
After 12 weeks of TX, FA values decreased in all WM structures compared to preTX, and then increased back 6 weeks after recovery (Table 1). However, these changes were not significant due to large variability in the data (Figure 4A).
Figure 4. Diffusion measurements. Mild and reversible decrease of FA after 12 weeks (12 w) of TX (A), although not significant. Reversible increase of RD in cCC, rCC, and EC (B). No significant changes in AD (C). Mild increase of MD at 12 weeks of TX and decrease at 6 weeks (6 w) without TX in rCC and EC (D). RD, AD, and MD values are in mm2/s. *p < 0.05.
RD values significantly increased 12 weeks after TX in cCC (p < 0.03), and non-significantly in rCC (p < 0.1) and in EC (p < 0.2) compared to preTX (Table 1). During the recovery phase, RD values fully returned to their initial values at 6 weeks in rCC (interval [1.1;13.8]), at 12 weeks in cCC (p < 0.03) and non-significantly in EC at 6 weeks (interval [−0.2;12.2]) (Table 1; Figure 4B). These RD results suggest clear demyelination during the TX phase in WM structures then remyelination during the recovery phase.
AD measurements showed no significant changes in rCC and EC (Figure 4C). In cCC, non-significant decrease of AD was measured at 12 weeks of TX, and at 6 weeks and 12 weeks without TX compared to before TX (Table 1), suggesting a progressive effect of the TX on AD values in cCC.
MD mildly increased in rCC and EC at 12 weeks of TX compared to before TX but not in cCC (Table 1, Figure 4D). After 6 weeks of recovery, MD values returned to initial values in rCC and in EC, however those results were not significant due to large variability in the data (Table 1).
In GM regions, no changes in diffusion metrics were detected.
Immunohistochemical evaluation of coronal brain sections at 12 weeks of TX confirmed demyelination in CC, EC, CPu, TH, and in S1 cortex identified as decreased GFP fluorescence. After 12 weeks of recovery a clear but less bright fluorescence reappeared in the same regions reflecting myelin regeneration. However, at this stage we found heterogeneity in the fluorescence intensity, which was more extended and more intense in CC and EC and showed intermediate intensity in GM regions, especially in the cortex. ROIs analyzed on MRI were analyzed in parallel by immunohistochemistry (Figure 5), showing that MRI changes with time were associated with myelin regeneration in the same regions.
Figure 5. Colocalization of demyelinated and remyelinated regions between MRI (A–K) and PLP/GFP immunohistochemical sections (A′–K′) before TX, 12 weeks (12w) after TX, and 12 weeks after TX removal. The dotted circle represents CPu and the arrow points to rCC.
We used the chronic CPZ demyelinating model and we showed that ultra-high-field MRI with a CryoProbe™ was sensitive for the detection and the quantification of demyelination and remyelination processes. Following the 12-week CPZ TX, T2w sequences, either by quantifying Sr or T2 values, could capture demyelination in WM areas such as in CC and in EC, but was also shown to be sensitive enough for measuring demyelination in the deep GM and in the cortex. Diffusion-weighted metrics were less sensitive to demyelination in the GM and could only quantify myelin loss and recovery (RD changes) in the main WM tracts (in accordance with already published data on the CPZ model treated for 6 weeks, Song et al., 2005; Zhang et al., 2012). When the neurotoxic agent was removed, a clear improvement of Sr and T2 value paralleling myelin regeneration on immunohistological samples was found both in the WM and in the deep GM, whereas in S1, only a mild trend to normalization of Sr was detected. In some regions, Sr and T2 values measurements showed varying levels of sensitivity in detecting demyelination (e.g., in CPu) or remyelination (e.g., in cCC or EC).
We also observed mild tremor and rigidity in mice under TX, which disappeared during recovery.
In this chronic 12-week TX paradigm we showed that a significant level of myelin regeneration could indeed occur within the 12 weeks that follow the interruption of TX, contrary to the previous idea that longer CPZ exposure was associated with failing remyelination (Armstrong et al., 2006). However, under this condition the remyelination was overall suboptimal and delayed compared to the classical 6-week TX paradigm where a complete remyelination is expected to occur within 4–6 weeks. This confers a major interest for the paradigm we used here, as it reproduces more closely the in vivo condition observed in human diseases such as MS, where remyelination is quite slow and incomplete. This system could provide an opportunity to better investigate candidate promyelinating drugs in this experimental model not only for their potential to accelerate the process of remyelination, but also for their ability to enhance the amount of myelin regeneration in unfavorable conditions.
Our results also indicate that the sensitivity of ultra-high-field MRI could be of interest to investigate myelin dynamics in GM regions, as a significant recovery was observed in deep GM regions together with a trend toward normalization of Sr in S1. Demyelinating lesions in the MS cortex were identified as strongly associated with physical and cognitive disability in MS (Calabrese et al., 2009), suggesting that their potential to remyelinate could be a crucial prognosis factor. On the other hand, pathological investigations have well attested that even in late stages of the disease, these lesions may retain a significant ability to spontaneously regenerate myelin (Chang et al., 2012). Therefore, the identification of putative promyelinating therapies positively acting on cortical remyelination has recently emerged as one of the key objective to reach in the regenerative approach for MS. The imaging methodology we used in the CPZ model may enable selection of candidate drugs depending on their impact on cortical repair. The smaller amount of myelin contained in the cortex compared to WM drastically decreases the sensitivity of the T2w sequence to myelin content changes, explaining why the recovery did not reach statistical significance using T2 measurements in this limited sample of animals. In addition, the ad libitum intake of CPZ could account for the large variability between mice, although the animals' weights were fairly similar. Further studies should include larger samples (however 5–8 mice were also used in most other similar studies, Song et al., 2005; Zhang et al., 2012) and may allow the detection of significant changes, especially when cortical remyelination is pharmacologically enhanced.
The use of both a very high magnetic field (11.7T) and a Cryoprobe in this study enabled very high resolution with high SNR in the T2w sequence with a voxel volume of 0.8 × 10−3 mm3 acquired in only 17 min, compared to voxel volumes used in similar studies with lower fields and conventional probes: from 1.6 × 10−3 mm3 at 2.35T (scan time not provided) (Merkler et al., 2005), to 3 × 10−3 mm3 in 20 min at 9.4T (Zhang et al., 2012), and to 7 × 10−3 mm3 in 10 min (Thiessen et al., 2013) and 10 × 10−3 mm3 (scan time not provided) (Chandran et al., 2012) at 7T. Our voxel volume was 2 to more than 10 times smaller than in other studies with comparable scan times, which conferred to our T2w protocol an increased sensitivity to detect signal changes in numerous WM and GM brain regions.
Although a disadvantage of T2w sequences could have been their non-specificity to a particular type of brain lesion, these sequences are highly sensitive, especially at very high resolutions (60 μm). In the model used, the requirement for sensitivity primed over specificity as the underlying pathology at the time that it was investigated and mainly consisted of myelin dynamic changes, with no edema or blood-brain barrier leakage, and only a minor inflammatory component as the microglial reaction predominates between the 3rd and the 5th week of TX and subsequently decreases in this model (Skripuletz et al., 2011).
Other sequences such as diffusion or magnetization transfer imaging were described as more specific for myelin compared to T2w sequences, however they suffer from lower spatial resolution, less reproducibility and worse SNR. While these sequences are of great interest for the quantitative investigation of the myelin compartment, they may be less sensitive to mild or moderate myelin dynamic changes, as attested by the negative results described in this study for diffusion parameters in the GM. Along the same line of results, magnetization transfer imaging showed some changes following the CPZ TX in the deep GM, but failed to detect any change in the cortex (Fjær et al., 2013).
Although T2 values are known to shorten with aging in normal mouse brains from about −0.05 to −0.1 ms/100 days as measured by Falangola et al. at 7T (Falangola et al., 2007), no significant changes in C57Bl6 WT mice were expected throughout our study as shown by Sun et al. MRM 2006 who also used 8-week old C57Bl6 mice for the first timepoint with a similar experimental protocol (longitudinal follow-up from 12-week of TX to 12-week of recovery, 4.7T). We calculated the estimated mean T2 values from those rates of changes for the control group over all timepoints. We found that the maximum percent change in T2 was −0.66% by the last timepoint (168 days later). From our data, we were able to detect significant T2 changes in the order of 3.2–30% between timepoints, which was 5–50 times larger than the estimated T2 changes of the control group over time. We can therefore consider that the significance of our T2 results would have remained unchanged even with an additional age-matched control group at each timepoint. Interestingly, a recent study (Jelescu et al., 2016) showed T2 reductions in the order of 8% over an 18-week period in the CC of similar control mice. These results suggest that T2 shortens more in regions highly dense in myelinated WM than regions poorly dense in WM as shown in Falangola's study.
Our analysis method was based on manually drawn ROIs and did not allow for systematic evaluation of the entire brain, which explains why the cerebellum and the cortex were not thoroughly examined so that more lesions could potentially be detected (e.g., in the cerebellar WM). However, automatic or semi-automatic measurement methods based on normalized ROIs on a template have limitations for very small regions such as CC or EC: errors in measurements can arise from misaligned ROIs and subsequent manual adjustments are necessary and time-consuming.
Overall this work emphasizes that ultra-high field MRI is sensitive enough to quantify dynamic demyelination and remyelination in the chronic CPZ model both in the WM and in the GM. This opens the perspective to investigate promyelinating compounds in vivo for their ability to promote repair in both regions, a step that will be crucial for the selection of molecules that should be further developed in early clinical trials in MS.
All authors substantially contributed to the study. AP performed the data acquisition and analysis and wrote the manuscript, MA performed the immunohistochemistry and wrote the manuscript, BS designed the study and wrote the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The reviewer FG and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.
All experiments were performed at the Brain and Spine Institute (Sorbonne Universités UPMC Univ Paris 06, UMR S 1127, CNRS UMR 7225, and ICM, F-75013, Paris, France). The research leading to these results has received funding from ARSEP (2014) and financial support from INSERM, from the program “Investissements d'avenir” ANR-10-IAIHU-06; from the program “Infrastructure d'avenir en biologie et santé” ANR-11-INBS-0006; from the Ile-de-France Region (DIM Cerveau et Pensée); and from IPRIAC (Institution de Prévoyance d'Inaptitude à la Conduite). We thank Dr. Lydia Yahia Cherif (CENIR-ICM) for her help in the statistical analyses.
CPZ, cuprizone; TX, treatment; WM, white matter; GM, gray matter; CC, corpus callosum; cCC, caudal corpus callosum; rCC, rostral corpus callosum; CP, cerebellar peduncle; EC, external capsule; CPu, caudate putamen; TH, thalamus; Sr, signal ratio.
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., and Zhou, Y. X. (2006). Endogenous cell repair of chronic demyelination. J. Neuropathol. Exp. Neurol. 65, 245–256. doi: 10.1097/01.jnen.0000205142.08716.7e
Boretius, S., Escher, A., Dallenga, T., Wrzos, C., Tammer, R., Brück, W., et al. (2012). Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI. Neuroimage 59, 2678–2688. doi: 10.1016/j.neuroimage.2011.08.051
Calabrese, M., Agosta, F., Rinaldi, F., Mattisi, I., Grossi, P., Favaretto, A., et al. (2009). Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch. Neurol. 66, 1144–1150. doi: 10.1001/archneurol.2009.174
Carlton, W. W. (1966). Response of mice to the chelating agents sodium diethyldithiocarbamate, alpha-benzoinoxime, and biscyclohexanone oxaldihydrazone. Toxicol. Appl. Pharmacol. 8, 512–521. doi: 10.1016/0041-008X(66)90062-7
Chandran, P., Upadhyay, J., Markosyan, S., Lisowski, A., Buck, W., Chin, C.-L., et al. (2012). Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 202, 446–453. doi: 10.1016/j.neuroscience.2011.10.051
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., et al. (2012). Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann. Neurol. 72, 918–926. doi: 10.1002/ana.23693
Falangola, M. F., Dyakin, V. V., Lee, S. P., Bogart, A., Babb, J. S., Duff, K., et al. (2007). Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease. NMR Biomed. 20, 343–351. doi: 10.1002/nbm.1163
Fjær, S., Bø, L., Lundervold, A., Myhr, K.-M., Pavlin, T., Torkildsen, O., et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLoS ONE 8:e84162. doi: 10.1371/journal.pone.0084162
Geurts, J. J., Roosendaal, S., Calabrese, M., Ciccarelli, O., Agosta, F., Chard, D. T., et al. (2011). Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 76, 418–424. doi: 10.1212/WNL.0b013e31820a0cc4
Jelescu, I. O., Zurek, M., Winters, K., Veraart, J., Rajaratnam, A., Shepherd, T. M., et al. (2016). In vivo quantification of demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy. Neuroimage 132, 104–114. doi: 10.1016/j.neuroimage.2016.02.004
Jenkinson, M., Bannister, P., Brady, J., and Smith, S. (2002). Improved optimisation for the robust and accurate linear registration and motion correction of brain images. NeuroImage 17, 825–841. doi: 10.1006/nimg.2002.1132
Kang, S. H., Li, Y., Fukaya, M., Lorenzini, I., Cleveland, D. W., Ostrow, L. W., et al. (2013). Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571–579. doi: 10.1038/nn.3357
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., et al. (2005). Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705–2712. doi: 10.1093/brain/awh641
Lindner, M., Kokuhi, J., Linsmeier, F., Trebst, C., and Stangel, M. (2009). Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett. 453, 120–125. doi: 10.1016/j.neulet.2009.02.004
Matsushima, G. K., and Morell, P. (2001). The neurotoxicant, cuprizone, as a model to study demyelination in the central nervous system. Brain Pathol. 11, 107–116. doi: 10.1111/j.1750-3639.2001.tb00385.x
Merkler, D., Boretius, S., Stadelmann, C., Ernsting, T., Michaelis, T., Frahm, J., et al. (2005). Multicontrast MRI of remyelination in the central nervous system. NMR Biomed. 18, 395–403. doi: 10.1002/nbm.972
Mike, A., Glanz, B. I., Hildenbrand, P., Meier, D., Bolden, K., Liguori, M., et al. (2011). Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am. J. Neuroradiol. 32, 515–521. doi: 10.3174/ajnr.A2340
Nelson, F., Poonawalla, A., Hou, P., Wolinsky, J., and Narayana, P. (2008). 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult. Scler. 14, 1214–1219. doi: 10.1177/1352458508094644
Skripuletz, T., Bussman, J.-H., Gudi, V., Koutsoudaki, P. N., Pul, R., Moharregh-Khiabani, D., et al. (2010). Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol. 20, 301–312. doi: 10.1111/j.1750-3639.2009.00271.x
Skripuletz, T., Gudi, V., Hackstette, D., and Stangel, M. (2011). De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol. Histopathol. 26, 1585–1597. doi: 10.14670/HH-26.1585
Skripuletz, T., Lindner, M., Kotsiari, A., Garde, N., Fokuhl, J., Linsmeier, F., et al. (2008). Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am. J. Pathol. 172, 1053–1061. doi: 10.2353/ajpath.2008.070850
Song, S. K., Sun, S. W., Ramsbottom, M. J., Chang, C., Russell, J., and Cross, A. H. (2002). Dysmyelination revealed through MRI increased radial (but unchanged axial) diffusion of water. Neuroimage 17, 1429–1436. doi: 10.1006/nimg.2002.1267
Song, S.-K., Yoshino, T. J., Le, T. Q., Lin, S.-J., Sun, S.-W., Cross, A. H., et al. (2005). Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 26, 132–140. doi: 10.1016/j.neuroimage.2005.01.028
Staugaitis, S. M., Chang, A., and Trapp, B. D. (2012). Cortical pathology in multiple sclerosis: experimental approaches to studies on the mechanisms of demyelination and remyelination. Acta Neurol. Scand. Suppl. 195, 97–102. doi: 10.1111/ane.12041
Sun, S.-W., Liang, H.-F., Trinkaus, K., Cross, A. H., Armstrong, R. C., and Song, S.-K. (2006). Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn. Reson. Med. 55, 302–308. doi: 10.1002/mrm.20774
Thiessen, J. D., Zhang, Y., Zhang, H., Wang, L., Buist, R., Del Bigio, M. R., et al. (2013). Quantitative MRI and ultrastructural examination of the cuprizone mouse model of demyelination. NMR Biomed. 26, 1562–1581. doi: 10.1002/nbm.2992
Turati, L., Moscatelli, M., Mastropietro, A., et al. (2015). In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice. NMR Biomed. 28, 327–337. doi: 10.1002/nbm.3253
Wu, Q. Z., Yang, Q., Cate, H. S., et al. (2008). MRI identification of the rostro-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model. J. Magn. Reson. Imaging 27, 446–453. doi: 10.1002/jmri.21111
Xiao, L., Xu, H., Zhang, Y., et al. (2008). Quetiapine facilitates oligodendrocytes development and prevents mice from myelin breakdown and behavioral changes. Mol. Psychiatry 13, 697–708. doi: 10.1038/sj.mp.4002064
Yu, O., Steibel, J., Mauss, Y., Guignard, B., Eclancher, B., Chambron, J., et al. (2004). Remyelination assessment by MRI texture analysis in a cuprizone mouse model. Magn. Reson. Imaging 22, 1139–1144. doi: 10.1016/j.mri.2004.08.017
Zaaraoui, W., Deloire, M., Merle, M., et al. (2008). Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4T. MAGMA 21, 357–362. doi: 10.1007/s10334-008-0141-3
Keywords: multiple sclerosis, demyelination, remyelination, cuprizone, T2, diffusion
Citation: Petiet A, Aigrot M-S and Stankoff B (2016) Gray and White Matter Demyelination and Remyelination Detected with Multimodal Quantitative MRI Analysis at 11.7T in a Chronic Mouse Model of Multiple Sclerosis. Front. Neurosci. 10:491. doi: 10.3389/fnins.2016.00491
Received: 05 August 2016; Accepted: 13 October 2016;
Published: 27 October 2016.
Edited by:John Ashburner, UCL Institute of Neurology, UK
Reviewed by:Mara Cercignani, Brighton and Sussex Medical School, UK
Francesco Grussu, University College London, UK
Copyright © 2016 Petiet, Aigrot and Stankoff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alexandra Petiet, email@example.com